Русский
Stent-associated urosepsis, personalized bacteriophage therapy
DOI: https://dx.doi.org/10.18565/urology.2024.4.97-102
Perepanova T.S., Kazachenko A.V., Mesropyan S.A., Antonova V.E., Nazirov M.R., Malova Yu.A., Lyubchenko L.N.
N.A. Lopatkin Research Institute of Urology and Interventional Radiology – branch of the National Medical Research Radiological Center, Moscow, Russia
In the era of antibiotic resistance, strict control of foci of infection (for example, a long-term stent) and adherence to the timing of drainage removal are necessary.
The spread of pan-resistant pathogens requires the development of effective alternative antimicrobial measures, in particular, bacteriophage therapy.
A clinical case of a 42-year-old patient with a closed spinal cord injury, lower paraplegia, pelvic organs dysfunction, post-traumatic right ureteral stricture, and right kidney stones is presented in the article.
The patient developed stent-associated urosepsis due to pan-resistant Klebsiella pneumonia after endoscopic removal of a long-term right ureteral stent (over 3 months) with endotoxic shock, disseminated intravascular coagulation syndrome and wound sepsis, which was treated using personalized local bacteriophage therapy.
The spread of pan-resistant pathogens requires the development of effective alternative antimicrobial measures, in particular, bacteriophage therapy.
A clinical case of a 42-year-old patient with a closed spinal cord injury, lower paraplegia, pelvic organs dysfunction, post-traumatic right ureteral stricture, and right kidney stones is presented in the article.
The patient developed stent-associated urosepsis due to pan-resistant Klebsiella pneumonia after endoscopic removal of a long-term right ureteral stent (over 3 months) with endotoxic shock, disseminated intravascular coagulation syndrome and wound sepsis, which was treated using personalized local bacteriophage therapy.
About the Autors
Corresponding author: T.S. Perepanova – Ph.D., MD, professor, Head of Infectious and Inflammatory Diseases and Clinical Pharmacology Panel of the Department of General and Reconstructive Urology of N.A. Lopatkin Research Institute of Urology and Interventional Radiology – branch of the National Medical Research Radiological Center, Moscow, Russia; e-mail: perepanova2003@mail.ru
Similar Articles
